Four Year Clinical Outcomes: Evaluating the Efficacy of Concomitant and Sequential Anthracycline-taxane Chemotherapy in Indian Breast Cancer Patients – A Regional Cancer Center Study
Journal of Current Oncological Trends · 2024
DOI: 10.4103/jcot.jcot_18_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Oncological Trends, 2024. Verfasst von Tanuma Mistry und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Breast cancer (BC) continues to be one of the most significant challenges in global public health, contributing to approximately 11.6% of all cancer cases worldwide. While anthracycline-taxane-based regimens have been established as a first-line treatment option, the majority of safety and efficacy data for these therapies originate from the high-income countries, leaving gaps in understanding their impact in low- and middle-income settings.
Objective
This study aims to report on clinical efficacy, toxicity, quality of life (QoL), and survival outcome of the following chemotherapeutic regimens: Anthracycline only (5-fluorouracil-epirubicin–cyclophosphamide), concomitant Docetaxel + Doxorubicin + Cyclophosphamide (TAC), and sequential Doxorubicin + Cyclophosphamide followed by Taxane (AC-T), among Indian BC patients in a high-volume tertiary cancer center. Materials and Methods: This study was conducted among histopathologically diagnosed 121 BC patients who received one of the aforementioned neo-adjuvant chemotherapies (NACTs) followed by surgery or surgery followed by adjuvant chemotherapy ± adjuvant radiation therapy ± hormone therapy. Clinical data, including patient demographics, tumor characteristics, treatment response, toxicity, QoL, and survival data, were collected and analyzed.
Results
Stage II–III (52.89%, 38.01%) with Grade II (84.3%) tumor was more frequently diagnosed. NACT group was categorized: Complete (12.5%), partial (34.37%), and nonresponders (NRs) (53.13%). Few patients faced chemo-induced high-grade toxicities alopecia (79.33%), anemia (1.6%), diarrhea (1.6%), and constipation (1.6%). QoL among BC patients noticed to be decreased significantly ( P < 0.05) with chemotherapy response during treatment but improved after the completion of chemotherapy (12 th month). A significant association was found between progression-free survival (PFS) in NACT and disease-free survival (DFS) in NRs group ( P < 0.0001). Although no significant difference was observed when three regimens were compared for PFS, overall survival, and DFS ( P > 0.05). TAC regimen (hazard ratio [HR] 1.585; 95% confidence interval [CI]: 0.441–5.694) and AC-T regimen (HR 1.077; 95% CI: 0.320–3.260) showed higher HRs ( P > 0.05).
Conclusions
This study was robust and not significantly different in the subgroup. All three regimens showed varying tolerance with minimal high-grade toxicity and comparable clinical efficacy and safety. While the AC-T regimen did not significantly improve survival; however, a positive trend was observed, suggesting its potential as a preferred option for certain patient cohorts, aligning with findings from Western studies. These results support the evidence-based optimization of chemotherapy regimens for BC management in the resource-limited settings.
Zitieren
APA
Mistry, T., Nath, P., Alam, N., & Nasare, V. D. (2024). Four Year Clinical Outcomes: Evaluating the Efficacy of Concomitant and Sequential Anthracycline-taxane Chemotherapy in Indian Breast Cancer Patients – A Regional Cancer Center Study. Journal of Current Oncological Trends. https://doi.org/10.4103/jcot.jcot_18_24
Vancouver
Mistry T, Nath P, Alam N, Nasare VD. Four Year Clinical Outcomes: Evaluating the Efficacy of Concomitant and Sequential Anthracycline-taxane Chemotherapy in Indian Breast Cancer Patients – A Regional Cancer Center Study. Journal of Current Oncological Trends. 2024. doi:10.4103/jcot.jcot_18_24
BibTeX
@article{Mistry2024,
author = {Mistry, Tanuma and Nath, Partha and Alam, Neyaz and Nasare, Vilas D.},
title = {Four Year Clinical Outcomes: Evaluating the Efficacy of Concomitant and Sequential Anthracycline-taxane Chemotherapy in Indian Breast Cancer Patients – A Regional Cancer Center Study},
journal = {Journal of Current Oncological Trends},
year = {2024},
doi = {10.4103/jcot.jcot_18_24}
}
EUVIMED